

集团亮点

Business Update

医渡科技蝉联“医疗大数据企业排行榜”榜首

Yidu Tech retained the top spot in the "Healthcare Big Data Enterprise Rankings"

中国科学院《互联网周刊》、德本咨询、eNet 研究院联合发布了“2022 医疗大数据企业排行榜”，医渡科技凭借前瞻性的医疗大数据和人工智能领域布局、创新的技术研发、成熟的场景应用以及亮眼的对医疗智能行业发展的贡献度和影响力，荣登榜首，这已是公司连续第四年获此殊荣。

Internet Weekly of the Chinese Academy of Sciences, Deben Consulting and eNet Research Institute jointly released the "2022 Healthcare Big Data Enterprise Rankings". Yidu Tech, by virtue of its forward-looking healthcare big data and layout in the field of AI, innovative technology R&D, mature scene application, and outstanding contribution and influence to the development of the healthcare intelligence industry, won the top spot, which is the fourth consecutive year that the company has won this honor.

2022医疗大数据企业排行榜

序号	企业
1	医渡科技
2	阿里健康
3	美年健康
4	京东健康
5	卫宁健康

2023. 02 互联网周刊/eNet 研究院/德本咨询联调

行业权威媒体专访医渡科技，科技创新打造惠民工程样本

Industry authoritative media interviewed with Yidu Tech, for its technological innovation in creating a sample of Huimin Insurance project

医渡科技旗下因数云 CEO 刘晟阳在中国银行保险报（中国银行保险监督管理委员会主管的唯一工作日报）专访中指出，大型“惠民保”项目尤其考验第三方平台产品设计、系统平台搭建、营销推广、客服与理赔服务、健康管理服务能力等综合一站式运营能力。这背后是对平台公司科技能力的大考验，需要丰富的运营场景迭代调优出来的算法支撑以及全方位的运营服务经验。

In an exclusive interview with *China Banking and Insurance News* (the only daily newspaper under the supervision of the China Banking and Insurance Regulatory Commission), Liu Shengyang, CEO of CausaCloud, a subsidiary of Yidu Tech, pointed out that large-scale Huimin Insurance projects require the comprehensive one-stop operation capabilities of third-party platform, including product design, system platform construction, marketing promotion, customer service and claims service, and health management service. This is a major test of the platform company's technological capabilities, requiring rich algorithm support from iterative optimization of operation scenarios and all-round operation service experience.

医渡科技连续两年担任“北京普惠健康保”“江苏医惠保 1 号”的主运营平台，同时也是“天津惠民保”的主运营平台。

For two consecutive years, Yidu Tech has been the main operating platform of Beijing Puhui Health Insurance and Jiangsu Huimin Insurance, as well as the main operating platform of Tianjin Huimin Insurance.

业务进展

Business Progress

医渡科技旗下医渡云承建“临床试验机构评价数据平台”建设

YiduCloud, a subsidiary of Yidu Tech, undertook the construction of Evaluation

Data Platform for Clinical Trial Institutions

医渡科技旗下医渡云与中国医学科学院北京协和医学院携手启动“临床试验机构评价数据平台”建设。这是继承建国家疾控中心“全球疫情数据分析和风险评估平台”，承建国家卫健委“药品临床综合评价数据管理平台”“全民基本药物制度监测评价信息系统”，承建国家药监局“药品安全主动监测研究平台”之后，医渡云承建的第五个全国性平台。该平台满足临床试验机构评价全流程工作，实现数据收集、评价模型的在线配置管理，为评价工作提供有效的质控、分析工具，助力高效分析决策。

YiduCloud, a subsidiary of Yidu Tech, and Peking Union Medical College of China Academy of Medical Sciences jointly launched the construction of Evaluation Data Platform for Clinical Trial Institutions, which is the fifth national platform built by YiduCloud after the Global Epidemic Data Analysis and Risk Assessment Platform of the Chinese Center for Disease Control and Prevention, the Data Management Platform for Comprehensive Clinical Evaluation of Drugs and the Monitoring and Evaluation Information System for National Essential Drug System of the National Health Commission, and the Active Monitoring and Research Platform for Drug Safety of the State Drug Administration. The platform meets the need for whole process evaluation of clinical trial institutions, realizes online configuration management of data collection and evaluation model, and provides effective quality control and analysis tools for evaluation to enhance efficient analysis and decision-making.

医渡云支持的国家「十三五」科技重大专项结题

The 13th Five-Year Plan of China Science and Technology Major Project supported by YiduCloud concluded

重庆医科大学附属第一医院呼吸与危重症医学科郭述良教授牵头，联合北京胸科医院、安徽省胸科医院、山东省公卫临床中心、兰州肺科医院，成功申报获得国家「十三五」科技重大专项「气管支气管结核精准诊治的新方法新策略研究」课题，医渡云科研协作平台有效支撑大规模、多中心科研课题开展，助力该课题一次性通过课题验收并结题。

The Department of Respiratory and Critical Care Medicine of the First Hospital of Chongqing Medical University, led by Prof. Guo Shuliang, together with Beijing Chest Hospital, Anhui Chest Hospital, Shandong Public Health Clinical Centre and Lanzhou Pulmonary Hospital, successfully applied for and won the project of "Research on New Methods and Strategies for Precise Diagnosis and Treatment of Tracheobronchial Tuberculosis" , a major scientific and technological project of the 13th Five-Year Plan in China. The research collaboration platform of YiduCloud effectively supported the development of large-scale, multi-center research projects, and helped the acceptance and conclusion of the project in one go.

作为一款一站式多中心临床数据采集工具，医渡云科研协作平台是基于医渡云在医疗人工智能领域的深耕和沉淀，依托专病库和医学数据智能平台建设的一站式新型多中心科研工具，为研究者提供便捷、安全、专业、高效的一站式科研服务，大幅度提高科研效率。


As a one-stop multi-center clinical data collection tool, YiduCloud Research Collaboration Platform is a new one-stop multi-center scientific research tool based on the accumulation of YiduCloud in the field of healthcare artificial intelligence, relying on disease registries and healthcare data intelligent platform to provide researchers with convenient, safe, professional and efficient one-stop scientific research services, and greatly improving scientific research efficiency.

医渡科技旗下 HLT 助力首款国产 3CL 抗新冠创新药上市，获“最佳合作伙伴”表彰
HLT, a subsidiary of Yidu Tech, helps launch the first domestic 3CL anti- SARS-CoV-2 innovative drug, and is awarded "Best Partner".

在先声药业首款国产 3CL 抗新冠创新药（先诺欣®）试验中，HLT 为其提供 DCT 数字化解决方案，以患者为中心，帮助项目顺利开展，助力产品加速上市，荣获“最佳合作伙伴”称号。

In the trial of Simcere's domestic 3CL anti-SARS-CoV-2 innovative drug (Xiannuoxin®), HLT provided DCT digital solutions to help the project run smoothly

and accelerate the launch of the product with a patient-centric approach, and was awarded the title of "Best Partner".



HLT 助力朗信生物 LX102 的 IIT 研究取得重要成果

HLT helps to achieve important results in the IIT study of Innostellar Bio LX102

近日，国家眼部疾病临床研究中心的李彤博士受邀在 Angiogenesis, Exudation, and Degeneration 2023 会议上介绍了朗信生物 LX102 的 IIT 研究的 1 年随访的成果，实现了一次给药零挽救治疗的重要里程碑。HLT 为 LX102 的 IIT 研究提供了数据管理和统计分析服务。

Recently, Dr. Li Tong from the National Center for Clinical Research of Eye Diseases was invited to present the one-year follow-up results of the IIT study of Innostellar Bio LX102 at the Angiogenesis, Exudation and Degeneration 2023 Conference, which achieved an important milestone of zero-rescue treatment with one dose. HLT provided data management and statistical analysis services for the IIT research of LX102.

HLT 临床数据科学建立了一套比较完善的眼科领域 CRF 图书馆，可以较好满足不同眼科治疗领域临床研究高质量快速建库（EDC）的需求，从根本上提升临床试验数据质量，为临床研究取得成功增加保障。

HLT Clinical Data Science has established a comprehensive CRF library in ophthalmology field, which can better meet the needs of high-quality electronic data capture(EDC) in clinical research in different ophthalmology treatment fields, fundamentally improving the quality of clinical trial data to ensure the success of clinical research.

HLT 中标某 MNC 药企的 III 期注册研究项目，因数智研 DCT 平台首次服务 MNC

HLT won the bid for the Phase III registration research project of an MNC pharmaceutical company, and Causa Research DCT platform served MNC for the first time

HLT 中标某跨国药企远程访视及远程招募项目，为其提供因数智研平台（远程智能临床试验一体化平台）及服务。

HLT won the bid for the remote interview and remote recruitment project of a multinational pharmaceutical company, providing it with the Causa Research Platform (an integrated platform for remote intelligent clinical trials) and services.

HLT 中标某 MNC 药企的系统综述项目，拓展多元化合作

HLT won the bid for a systematic review project of an MNC pharmaceutical company to expand diversified cooperation

HLT 中标某 MNC 药企“中国肺动脉高压 (PAH) 的流行病学、自然病史、人文和经济负担：系统综述 (SLR)”项目，这是 HLT 海外业务组近期与该 MNC 药企合作的第四个项目，也是 HLT 首个和该总部合作的 SLR 项目。这表明 HLT 与 MNC 药企的合作越来越多元化，HLT 在 SLR 项目上积累更多经验，为后续合作打下基础，后续在谈项目正在有序推进中。

HLT won the bid for the project "Epidemiology, Natural History, Humanities and Economic Burden of Pulmonary Hypertension (PAH) in China: Systematic Review (SLR)" of an MNC pharmaceutical company, which is the fourth project that HLT's

overseas business team has recently cooperated with this MNC pharmaceutical company, and is also the first SLR project that HLT has cooperated with the headquarters of the MNC pharmaceutical company. This shows that the cooperation between HLT and the MNC pharmaceutical companies is becoming more and more diversified, and HLT has accumulated more experience in SLR projects, laying the foundation for follow-up cooperation, with subsequent projects under negotiation in an orderly manner.

HLT 中标某 MNC 药企的流感真实世界数据分析项目，以证据驱动决策

HLT won the bid for the real-world influenza data analysis project of an MNC pharmaceutical company, with an evidence-driven decision

HLT 通过大样本量流感真实世界数据，为 MNC 药企制定产品研发策略提供决策依据；联动 MNC 药企的 global 部门，将中国人群与国际人群做比较，助力 global 证据生成。

HLT assists MNC pharmaceutical company to formulate and decide product research and development strategies through a large sample of real-world influenza data. HLT also works with the global department of the MNC pharmaceutical company to compare the Chinese populations with international populations to help generate global evidence.

行业洞察

Industry Insights

全国政协委员建议加强数据利用，推动精准医疗发展

CPPCC member suggested strengthening data utilization and promoting the development of precision medicine

2023 年全国两会召开前，全国政协委员、中国医学科学院肿瘤医院肝胆外科副主任赵宏提出，我国需高度重视促进健康医疗数据的共享和应用，切实支持精准医疗的深入发展，构建核心国际竞争力，促进人民健康水平提升。

Before the NPC and CPPCC in 2023, Zhao Hong, a member of Chinese People's Political Consultative Conference and deputy director of the Department of Hepatobiliary Surgery at the Cancer Hospital of China Academy of Medical Sciences, proposed that China needs to attach great importance to promoting the sharing and application of health care data and effectively support the in-depth development of precision medicine to build core international competitiveness and promote people's health.

精准医疗的方向逐渐成为共识，医疗智能企业也正在迎来更广阔的发展空间。医渡科技一直坚守“绿色医疗”（普惠的精准医疗）的初心，多年来持续投入大数据、AI等前沿技术的研发，推动技术价值落地医疗场景，助力精准医疗发展。

The direction of precision medicine has gradually become a consensus, and healthcare intelligence enterprises are also welcoming a broader development space. Yidu Tech has always adhered to the vision of "green healthcare" (inclusive precision healthcare), and has continued to invest in the research and development of cutting-edge technologies such as big data and AI for years to promote the technical value of the healthcare scene and help the development of precision healthcare.

投资者交流

Investor Communication

高盛、招银国际维持医渡科技买入评级

Goldman Sachs and CMB International maintain a Buy rating on Yidu Tech

高盛发研报指，该行调整医疗技术与服务领域相关股份的预测及估值基准年，以反映重新开放、业务环境正常化以后的影响及复苏可见度，维持医渡科技“买入”评级，目标价为 16 港元。

Goldman Sachs issued a research note stating that the bank has adjusted its forecasts and valuation base year for shares related to the healthcare technology and services sector to reflect the impact of re-opening, normalization of the business environment

and recovery visibility, and maintained a Buy rating on Yidu Tech with a target price of HK\$ 16.

招银国际维持医渡科技买入评级，目标价为 14.07 港元。

CMB International maintained a Buy rating on Yidu Tech with a target price of HK\$ 14.07.

民生证券发布研究报告，建议关注医渡科技

Minsheng Securities releases research report suggesting focus on Yidu Tech

民生证券发布的《医疗 IT 行业动态报告：医保数据要素改革商业空间详细测算》中指出，未来，在政府引导下，国家将持续完善医保数据授权运营机制，提升医疗数据开放覆盖程度，建议关注医渡科技等标的。

In the *Dynamic Report of Healthcare IT Industry: Detailed Measurement of Business Space for Medical Insurance Data Elements Reform* released by Minsheng Securities, it is pointed out that in the future, under the guidance of the government, the country will continue to improve the operation mechanism of medical insurance data authorization and improve the open coverage of healthcare data, suggesting the focus on Yidu Tech.

医渡科技投资者内部交流会：稳健性与成长性兼具，医疗智能行业空间广阔

Yidu Tech's internal communication conference with investors: stability and growth, and broad space in healthcare intelligence industry

智通财经举办“公司面对面·第一期——医渡科技投资者内部交流会”，医渡科技就公司的业务发展及亮点与投资者进行了沟通。交流中提到，医渡科技下一步将继续坚持“一横一纵”战略，扩大基建网络、加深对疾病研究，聚焦业务、疾病、客户、组织，助力医疗智能生态打造，不断推动医疗产业智能化升级、高质量发展。

Zhitong Finance held the *Company Face to Face Phase I: Yidu Tech's Internal Communication Conference* with investors, in which Yidu Tech communicated with investors on the company's recent development and business highlights. It was mentioned that Yidu Tech will continue to adhere to the 'one horizontal + one vertical'

strategy, expand the infrastructure network, deepen the research on diseases, focus on business, diseases, customers and organizations, help build a healthcare intelligent ecology, and constantly promote the intelligent upgrading and high-quality development of the healthcare industry.